Prognostic significance of FoxM1 expression in non-small cell lung cancer.
BACKGROUND
Various studies examined the relationship between FoxM1 overexpression with the clinical outcome in patients with non-small cell lung cancer (NSCLC), but yielded conflicting results.


METHODS
Electronic databases updated to Jan 01, 2015 were searched to find relevant studies. A meta-analysis was conducted with eligible studies which quantitatively evaluated the relationship between FoxM1 overexpression and survival of patients with NSCLC Survival data were aggregated and quantitatively analyzed.


RESULTS
We performed a meta-analysis of seven studies (n=860 patients) that evaluated the correlation between FoxM1 overexpression and survival in patients with NSCLC. Combined hazard ratios suggested that FoxM1 overexpression was associated with poor prognosis of overall survival (OS) (HR =1.73, 95% CI: 1.32-2.14) in patients with NSCLC.


CONCLUSIONS
FoxM1 overexpression indicates a poor prognosis for patients with NSCLC.
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Qing
Q
Sun
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Min
M
Dong
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Yujuan
Y
Chen
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Jiawei
J
Zhang
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Jinpeng
J
Qiao
Department of Oncology, Wuxi No. 2 People's Hospital, Nanjing Medical University, Wuxi 214002, China.
Xuedan
X
Guo
FoxM1; lung cancer; meta-analysis; prognosis